AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05257590
Drug: CVM-1118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVM-1118 will be administered 200 mg, PO, BID with an option to increase the starting dose to 300 mg, PO, BID for the subsequent subjects following assessment of safety data from the initial 10 subjects.
Trial: NCT05754411
Drug: [14C]STI-1558
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting oral administration of 600 mg \[ 14C \] STI-1558 ( about 100 μCi ) solution.
Trial: NCT00001059
Drug: Doxorubicin hydrochloride (liposomal)
RxNorm normalized name: DOXORUBICIN HYDROCHLORIDE LIPOSOME
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06093542
Drug: AZD7053
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomised participants will receive AZD7503 subcutaneously.
Trial: NCT06093542
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomised participants will receive placebo subcutaneously.
Trial: NCT05084079
Drug: CSII with formula-based initial insulin regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial total daily insulin dose(TDD) for CSII was calculated with a formula :（estimate TDD-1(eTDD-1) = 0.35× body weight (kg) + 2.05× FPG (mmol/L) + 4.24×triglyceride(mmol/L) + 0.55× waist circumference (cm) - 49.1）, 42% of which was assigned as total basal dose and 58% as total premeal dose, with the pre-meal doses divided into 30:35:35 for breakfast, lunch and dinner.
Trial: NCT05084079
Drug: CSII with weight-based initial insulin regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDD for CSII was started with 0.5 IU/kg, 50% of which was assigned as total basal dose and 50% as total premeal dose, and the total pre-meal dose was divided equally before each meal.
Trial: NCT00001033
Drug: Pyridoxine hydrochloride
RxNorm normalized name: Pyridoxine Hydrochloride
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05871424
Drug: placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simple dressing tape only will be applied
Trial: NCT05466643
Drug: DWP16001 0.3mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet, Orally, Once daily single dose
Trial: NCT05466643
Drug: DWP16001 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet, Orally, Once daily single dose
Trial: NCT05497739
Drug: Adjuvant systemic chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 85 mg/m\^2 on Day 1; S-1 depends on Body Surface Area (BSA), 40 mg Bid, Days 1-10 (BSA \< 1.25 m\^2), 50 mg Bid, Days 1-10 (BSA 1.25-1.50 m\^2), 60 mg Bid, Days 1-10 (BSA \> 1.50 m\^2).
Trial: NCT06315972
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: add-on placebo + aerobic exercise training
Trial: NCT04923594
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosed orally, once daily for up to 4 weeks.
Trial: NCT06549504
Drug: AG2202T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG2202T Single-dose
Trial: NCT06549504
Drug: AG2202R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG2202R Single-dose
Trial: NCT03451487
Drug: Panadol®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 500mg Tablet
Trial: NCT03451487
Drug: SafeTynadol®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 500mg Tablet
Trial: NCT06190470
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is similar to Cannabis product but do not contain THC.
Trial: NCT05210088
Drug: Hypoxia, intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The device used to generate the intermittent hypoxia stimulus is a gas mixer used in current clinical practice and research (Altitrainer®, SMTEC S.A. Switzerland). The hypoxic stimulus will be obtained by having the subject inhale a gas mixture enriched in nitrogen by means of a mask, in variable proportion according to the desired degree of hypoxia.~Hypoxic conditioning will be performed in three one-hour sessions per week, performed non-consecutively, for 8 weeks. The hypoxic stimulus will be intermittent, and each session will consist of 7 cycles of 5 minutes of hypoxia alternating with 3 minutes of normoxia (FiO2 = 21%). The subjects will be installed in a semi-recumbent position, at rest in a quiet environment.~For hypoxic exposure, the inspired fraction of oxygen (FiO2) will be set individually to achieve the targeted level of desaturation (Pulse Oxygen Saturation, SpO2) continuously monitored.
Trial: NCT03654040
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg/kg administered intravenously (IV) following leukapheresis and between 1 to 3 days prior to Treg product (arTreg) infusion, per institutional standard of care.
Trial: NCT06314906
Drug: Antiemetic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral olanzapine at a dose of 5 mg per day on days 1 through 4, along with NK1 receptor antagonist, 5HT3 receptor antagonist, and intravenous dexamethasone at a dose of 10 mg 30 minutes prior to chemotherapy on Day 1, followed by intravenous dexamethasone at a dose of 8 mg on days 2, 3, and 4 post-chemotherapy.
Trial: NCT06314906
Drug: Antiemetic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: They will also receive the same antiemetic medications as the experimental group.
Trial: NCT05424835
Drug: Pyrotinib in combination with Capecitabine.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib in combination with Capecitabine.
Trial: NCT05820841
Drug: R-miniCHOP
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Rituximab i.v.: 375 mg/m2 (D0)~* Cyclophosphamide i.v.: 400 mg/m² (D1)~* Doxorubicin i.v.: 25 mg/m² (D1)~* Vincristine i.v.: 1 mg (D1)~* Prednisolone p.o.: 40 mg/m² (D1 to D5).~Cycles repeated every 3 weeks
Trial: NCT05111197
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with a maximum of 5 residual hypermetabolic lesions observed on 18F- FDG PET / CT after a minimum of 6 months of immunotherapy continue their anti-PD-1 or anti-PD-L1 immunotherapy as it was administered before randomization in the trial, according to the standards.
Trial: NCT05209620
Drug: ICP-022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction Chemotherapy: Orelabrutinib, 150mg/d continuous oral administration (3 weeks/cycle, total 6 cycles).~Maintenance Treatment: Orelabrutinib, 150mg/d continuous oral administration (28d/cycle).
Trial: NCT06215820
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: over-encapsulated tablet and/or tablet
Trial: NCT06216041
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAD and MAD adopt sentinel method which 2 healthy subjects first will receive IMM-H014, and if are evaluated to be tolerable, the remaining 8 subjects will be randomly assigned to receive IMM-H014 and placebo in a ratio of 3:1(10 in per experimental Cohort).
Trial: NCT06216041
Drug: Placebo ( FE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FE part is divided into two groups: 8 subjects will receive IMM-H014 and 2 subjects will receive placebo In group A .All 8 subjects will receive IMM-H014 in group B. Group A adopts sentinel method .The treatment in food effect consists of 2 periods.
Trial: NCT06107374
Drug: [18F]F-AraG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two PET scans
Trial: NCT06448130
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo+ lifestyle intervention
Trial: NCT04764097
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00930995
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT04625101
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-active dosage form.
Trial: NCT06228482
Drug: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be undergo \[68Ga\]Ga DOTA-5G PET/CT scans to confirm eligibility for the \[177Lu\]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of \[68Ga\]Ga DOTA-5G PET/CT will be offered therapy. Patients will undergo a follow up \[68Ga\]Ga DOTA-5G PET/CT scans to assess tretament efficacy.
Trial: NCT06297174
Drug: HIDRASEC®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIDRASEC® (reference drug)
Trial: NCT06176781
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection Simulants(Edaravone Dexborneol concentrated solution for injections) administered intravenously for 5 - 10 days, and then followed by Sublingual Tablet Simulants(Edaravone Dexborneol Sublingual Tablets) BID administered sublingually for the last days, the total duration of treatment was 14 days
Trial: NCT05447520
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet once daily
Trial: NCT05447520
Drug: Conventional DMARDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methotrexate, leflunomide, hydroxychloroquine or sulfasalazine
Trial: NCT06391008
Drug: Evoximab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evoximab (20mg/kg, Q3W)
Trial: NCT04733651
Drug: Hospital standard of care for COVID-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care for COVID-19 as per the hospital guidelines
Trial: NCT05729555
Drug: Compound ibuprofen polyrelease tablets
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specification: Each tablet containing ibuprofen 400 mg, diphenhydramine hydrochloride 50 mg Batch number: 22082801 Content: Ibuprofen 96.9%, diphenhydramine hydrochloride 102.4% Effective: August 27,2024 S torage conditions: sealed, room temperature. Manufacturers: Overseas Pharmaceuticals, Ltd. Usage and dosage：Once a day, one tablet at a time
Trial: NCT05729555
Drug: reference 1 (R1): Ibuprofen Tablets (Motrin IB®)reference 2 (R2): Diphenhydramine Hydrochloride Tablets (Benadryl®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specification: 200 mg Batch number: 2CE2330 Content: 100.5% Expiry date: December 2023 Storage conditions; Storage in 20℃ -25℃ manufacturer: JOHNSON \& JOHNSON CONSUMER INC. Usage and dosage：Once a day, two tablets at a time~Specification: 25 mg Batch number: BCC009 Content: 99.2% Effective to: December 2023 storage conditions; storage at 20℃ -25℃, shading manufacturer: JOHNSON \& JOHNSON CONSUMER INC Usage and dosage：Once a day, two tablets at a time
Trial: NCT06219915
Drug: Carbidopa-Levodopa 25/100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take one 25/100mg carbidopa-levodopa tablet 3 times a day on days 4-6, then increase to 1.5 tablets 3 times a day on days 7-10.
Trial: NCT06219915
Drug: Placebo 1
RxNorm normalized name: placebo 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take one 25mg placebo tablet 3 times a day for 10 days.
Trial: NCT06219915
Drug: Placebo 2
RxNorm normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take one 100mg placebo tablet 3 times a day on days 4-6, then increase to 1.5 tablets 3 times a day on days 7-10.
Trial: NCT05082766
Drug: enhanced DefenAge 8-in-1 BioSerum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DefenAge is a topical skincare brand containing a composition of biologically active natural molecules, named defensins, that repair skin damage associated with aging.
Trial: NCT02016495
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06374888
Drug: Neratinib maleate in combination with capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neratinib maleate tablets，Tablets, 40mg/ tablet, 180 tablets/bottle, orally, 240mg once daily, sealed, stored not above 25℃
Trial: NCT04871828
Drug: Leukotriene Receptor Antagonist
RxNorm normalized name: Leukotriene receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zafirlukast
Trial: NCT05363722
Drug: IBI310（0.5mg/kg）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI310 0.5mg/kg IV d1 Q6W
Trial: NCT05363722
Drug: IBI310（0.3mg/kg）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI310 0.3mg/kg IV d1 Q6W
Trial: NCT04853342
Drug: Drug: Furmonertinib 80 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial dose of Furmonertinib 80 mg once daily
Trial: NCT04853342
Drug: Furmonertinib 80 mg placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial dose of Furmonertinib 80 mg once daily
Trial: NCT06284226
Drug: Allogeneic NK（CCT-ANK-11)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: allogeneic natural killer cells
Trial: NCT05538949
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1Drop, QD / Day1, BID / Day5\~Day8.
Trial: NCT05862974
Drug: LPM3480392
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 30min duration
Trial: NCT05862974
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 30min duration
Trial: NCT05023811
Drug: [14C]RIST4271
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]RIST4271 oral solution
Trial: NCT05300490
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In this routine care study, all patients will receive a joint injection of prednisolone at a dose left to the discretion of the physician. The urinary excretion kinetics of this product and its metabolites will then be followed at different times. An association with metabolic genetic profile will be done.
Trial: NCT06429501
Drug: Bupivacaine/Epinephrine
RxNorm normalized name: BUPIVACAINE/EPINEPHRINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection
Trial: NCT04742673
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to the placebo arm will receive intravenous normal saline when they exhibit ICU delirium.
Trial: NCT05798572
Drug: Sildosin group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group had flexible ureteroscopy (F-URS) with preoperative daily uptake of 8 mg silodosin for one week.
Trial: NCT05094934
Drug: NNC0385-0434 A 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive the same dose (100 mg) of the study medicine NNC0385-0434, which will be given for 10 days in a row. Participants will get the study medicine in a tablet taken orally once-daily. The study medicine needs to be taken in the morning after overnight fasting and 30 minutes before the first meal of the day.
Trial: NCT04968899
Drug: Neofordex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dexamethasone (Neofordex®) 40 mg (Day1 to Day 4), ± an additional 4-days cycle of dexamethasone between days 10 and 21.
Trial: NCT04968899
Drug: Intravenous immunoglobulins
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIg (1g/kg D1-D2) plus oral prednisone (1 mg/kg/day x 21 days (3 weeks))
Trial: NCT05911360
Drug: DTG/3TC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTG/3TC FDC will be administered once daily.
Trial: NCT04884217
Drug: Pro-ocular™ Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pro-ocular™ Topical Gel 1% is applied dermally to the forehead twice-daily
Trial: NCT04884217
Drug: Placebo Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a toopical gel without active ingredient applied dermally to the forehead twice-daily
Trial: NCT06377397
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In experimental arm, intravenous antibiotics as per the written down empirical antibody policy of the unit will be administered selectively to those newborn infants who later develop clinical signs of sepsis according to a predefined repertory of clinical signs.~In active comparator arm, intravenous antibiotics as per the written down empirical antibody policy of the unit will be administered pre-emptively to all newborn infants from enrollment even if they do not have any clinical signs of sepsis at enrollment
Trial: NCT03595150
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac rectally given before the ERCP to prevent pancreatitis
Trial: NCT06102512
Drug: [¹⁴C]-LOXO-783
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT06102512
Drug: [¹⁴C]-LOXO-783
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT06442566
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: double-blinded randomization to placebo or transdermal buprenorphine
Trial: NCT05656222
Drug: VIA combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a 90-minute intravenous infusion of irinotecan at a dose of 50 mg/m2/d for 5 days every 3 weeks, vincristine given at a dose of 1.4 mg/m2 (maximum 2 mg) on days 1 and 8, and oral administration of Anlotinib once daily on days 1-14 within a 21-day cycle.
Trial: NCT05132179
Drug: Dakins Full Strength Solution, 0.5% Topical Solution, HOCl solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dakin´s solution is a 50/50 mixture of 1% sodiumhypochlorite and 2% sodiumhydrocarbonate, the mixture is a 0,5% chlorine solution. Dakin´s solution is not used in Sweden on wound. Dakin´s solution is only used in dental care in Sweden.
Trial: NCT05603559
Drug: 1.1 GBq (30 mCi) of 177Lu-P17-087
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients were intravenous injected with single dose 1.1 GBq (30 mCi) of 177Lu-P17-087 then monitored at 1.5 hours, 4 hours, 24 hours, 48 hours, 72 hours, 120 hours and 168 hours post-injection.
Trial: NCT05603559
Drug: 1.1 GBq (30 mCi) of 177Lu-P17-088
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients were intravenous injected with single dose 1.1 GBq (30 mCi) of 177Lu-P17-088 then monitored at 1.5 hours, 4 hours, 24 hours, 48 hours, 72 hours, 120 hours and 168 hours post-injection.
Trial: NCT05109663
Drug: SKLB1028
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKLB1028, capsule, oral
Trial: NCT00000644
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05512039
Drug: Botox 50 Unit Injection
RxNorm normalized name: onabotulinumtoxinA 200 UNT [Botox]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to either receive a standard dose (100 units) or reduced dose (50 units) of onabotulinumtoxinA. If a participant has decreased symptom relief they may receive repeat treatment up to twice during the 12 month follow-up period, with minimum 4 month intervals between treatments.
Trial: NCT05454462
Drug: IMP Application KM-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KM-001 will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. the patient will use IMP twice a day for 28 days.
Trial: NCT06389344
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same amount of normal saline will be infused intravenously at a constant speed within 30 min after tracheal intubation/pneumatectomy fixation.
Trial: NCT05512039
Drug: Botox 100 Unit Injection
RxNorm normalized name: onabotulinumtoxinA 100 UNT [Botox]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to either receive a standard dose (100 units) or reduced dose (50 units) of onabotulinumtoxinA. If a participant has decreased symptom relief they may receive repeat injection up to twice during the 12 month follow-up period, with minimum 4 month intervals between treatments.
Trial: NCT05370976
Drug: Cytotect®CP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytotect®CP in two phases:~Induction phase: 1 ml/kg/week for 4 weeks Maintenance phase: 1 ml/kg/2 weeks for 12 weeks or corticosteroid dose \< 0.5 mg/kg, according to which condition occurs first.~Patients developing CMV infection under Cytotect®CP must be given standard anti-CMV treatment (Gancyclovir or Foscarnet) according to their center procedure. Cytotect®CP will be maintained
Trial: NCT06271681
Drug: 15-valent pneumococcal conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDA approved pneumococcal vaccines 15 valent conjugate vaccine administered at enrollment
Trial: NCT05293600
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule 30 min before bedtime
Trial: NCT05733741
Drug: Preservative-free Benoxinate hydrochloride 0.4% (Benoxidia unit-dose vials [UD], Orchidia pharmaceutical Ind., Egypt)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For each patient, one eye was treated with preservative-free Benoxinate hydrochloride 0.4%.~The prescribed regimen comprises of the instillation of one drop immediately, 2, 4, 6 and 8 hours after the end of surgery.~Every patient was given 5 UD vials only of preservative-free Benoxinate hydrochloride 0.4% at each follow up visit for the next postoperative day usage administered 5 times daily (every 3 hours while awake) for the first 3 postoperative days giving clear instructions to immediately discard the vial after single use.
Trial: NCT05085275
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will be instructed to take study drug (ferric citrate or placebo) at a fixed dose of 2 tablets per meal or snacks, up to three times per day. The maximum dose is 6 tablets per day. No additional tablets (beyond a total of 6 per day) should be taken. Tablets should not be crushed or chewed.
Trial: NCT04941183
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo